Flow of Progress: Optimizing Current Treatment Strategies and the Pharmacist's Role in Benign Prostatic Hyperplasia

Pharmacy Times, November 2013 Cough & Cold, Volume 79, Issue 11

Pharmacists can learn about current treatment strategies for the management of benign prostatic hyperplasia, including special considerations in managing comorbidities.

Flow of Progress: Optimizing Current Treatment Strategies and the Pharmacist’s Role in Benign Prostatic Hyperplasia

Shilpa Amara, PharmD

Drug Information Specialist

Barnabas Health

West Orange, New Jersey

Disclosures

The following contributors have no relevant financial relationships with commercial interests to disclose.

Faculty

Shilpa Amara, PharmD

Pharmacy Times Office of Continuing Professional Education

Planning Staff—Judy V. Lum, MPA, and Steve Lin, PharmD

Pharmacy Times Editorial Staff

Kirk McKay and David Allikas

PTOCPE uses an anonymous peer reviewer as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.

LEARNING Objectives:

Upon completion of this educational activity, participants should be able to:

  • Discuss the epidemiology and pathophysiology of benign prostatic hyperplasia(BPH).
  • Recognize the impact of BPH on patients and their quality of life.
  • Examine current treatment strategies for the management of BPH, including special considerations in managing comorbidities.
  • Discuss the pharmacist’s role in managing BPH, including addressing treatment expectations, medication safety, and patient compliance.

Target audience: Pharmacists

Type of activity: Knowledge

Release date: November 12, 2013

Expiration date: November 12, 2015

Estimated time to complete activity: 2 hours

Click here to view this activity.

This activity is supported by an educational grant from Watson Laboratories, Inc.

Pharmacy Times Office of Continuing Professional Education is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 2.0 contact hours (0.2 CEUs) under the ACPE universal activity number 0290-0000-13-159-H01-P. The activity is available for CE credit through November 12, 2015.